Unmet Needs and the Future of HER2+ Breast Cancer Treatment
The panel closes their discussion by summarizing the most exciting recent advances in HER2+ breast cancer, the future of treatment, and unmet needs that must be addressed.
Emerging Data and Investigational Agents in HER2+ mBC
The panel highlights emerging data from SABCS 2022 on investigational agents being explored for HER2+ mBC treatment.
Use of MRI for Surveillance of Brain Metastases in Patients with HER2+ mBC
The panel discusses the management of patients with HER2+ mBC with asymptomatic brain mets and shares their thoughts on the use of surveillance brain MRI in this setting.
Second-Line Treatment of HER2+ mBC and Recent Data Updates
Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).
Options for Third- and Further-Line Treatment of HER2+ mBC
Dr Debu Tripathy explains the treatment options for patients with HER2+ metastatic breast cancer in the third-line and later-line settings, including combination tucatinib/trastuzumab/capecitabine.
Data Updates in Adjuvant HER2+ Early Breast Cancer from SABCS 2022
The panel highlights recent data updates in adjuvant treatment of HER2+ early breast cancer, including longer-term follow-up data from the APT and ATEMPT trials.
HER2+ mBC: First-Line Treatment Regimens
A focused discussion on available options for the first-line treatment of HER2+ metastatic breast cancer (mBC), with reference to data from the CLEOPATRA trial.
Extended Adjuvant Neratinib Therapy for Patients with HER2+ Early Breast Cancer
Joyce O’Shaughnessy, MD, starts a conversation on which patients with HER2+ early breast cancer are the best candidates for extended adjuvant neratinib therapy.
Clinical Data Updates on Adjuvant Pertuzumab/Trastuzumab for HER2+ Early Breast Cancer
A review of recently reported data on the use of adjuvant pertuzumab/trastuzumab for the treatment of HER2+ early breast cancer, including data from the APHINITY and PHranceSCa trials.
Expert Perspectives on Clinical Experience with Ado-Trastuzumab Emtansine (T-DM1)
The panel explains their clinical experiences with using the antibody-drug conjugate (ADC) ado-trastuzumab emtansine (T-DM1) to treat HER2+ early breast cancer.
Factors Informing Adjuvant Treatment Selection in HER2+ Early Breast Cancer
A look at how patient response to neoadjuvant treatment for HER2+ early breast cancer informs adjuvant treatment selection.
Subcutaneous vs Intravenous Pertuzumab/Trastuzumab for Treatment of HER2+ Early Breast Cancer
The panel shares the factors that influence whether they recommend a subcutaneous or intravenous formulation of pertuzumab/trastuzumab in addition to chemotherapy.
De-Escalation Approaches in Patients with HER2+ Early Breast Cancer
Debu Tripathy, MD, details when he utilizes a treatment de-escalation approach in his patients with HER2+ early breast cancer.
Neoadjuvant Treatment of HER2+ Early Breast Cancer
A review of the standard of care regimens for the preoperative or neoadjuvant treatment of HER2+ early breast cancer.
Incidence and Typical Prognosis of HER2+ Early Breast Cancer
Virginia Borges, MD, explains how common HER2+ early breast cancer is and the goals of treatment for patients.
Further Understanding of Immune Mechanisms in Tumor Microenvironment Is Key to Advancing Immunotherapy in Solid Tumors
Navigating Systemic Therapy for RCC: Balancing Risk Status and Response
ADCs, Novel Targets Represent Next Wave of Treatment Advances in mCRPC
Precision Medicine in Prostate Cancer Care: Keeping Up With Evolving Guidance for Testing and Decision Making
2 Clarke Drive Cranbury, NJ 08512